ArticleCancer research and treatment2016
Association between Mutation and Expression of
Article in Cancer research and treatment, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 64 citations in OpenAlex.
- Molecular characterization of mammary mucinous cystadenocarcinoma reveals recurrent TP53 and RB1 alterations with frequent PI3K-AKT pathway abnormalities.Virchows Archiv : an international journal of pathology · 2026Article
- Bioinformatics Analysis of the miR-15 Family Members and Their Potential Target Genes in Breast Cancer Progression.Advanced biomedical research · 2026Article
- The impact of p53 mutation on tumor immune evasion: mechanistic insights and clinical implications.Frontiers in immunology · 2026Review
- Effect of microRNA-141-3p, E2F3, CDK3, and KAT2B overexpression on histologic tumor grade and metastasis status in untreated breast cancer tissues.BioImpacts : BI · 2025Article
- Immunohistochemical Characterization of a Large Cohort of Triple Negative Breast Cancer.International journal of surgical pathology · 2024Article
- Article
- Exploring Biomarkers in Breast Cancer: Hallmarks of Diagnosis, Treatment, and Follow-Up in Clinical Practice.Medicina (Kaunas, Lithuania) · 2024Review
- Prognostic Factors for Triple-Negative Breast Cancer with Residual Disease after Neoadjuvant Chemotherapy.Journal of personalized medicine · 2023Article
- Checkpoint Kinase 1 (CHK1) Functions as Both a Diagnostic Marker and a Regulator of Epithelial-to-Mesenchymal Transition (EMT) in Triple-Negative Breast Cancer.Current issues in molecular biology · 2022Article
- Effect of Dickkopf-1 (Dkk-1) and SP600125, a JNK Inhibitor, on Wnt Signaling in Canine Prostate Cancer Growth and Bone Metastases.Veterinary sciences · 2021Article
- Curcumin: Modulator of Key Molecular Signaling Pathways in Hormone-Independent Breast Cancer.Cancers · 2021Review
- Oncogenic and Tumor Suppressive Components of the Cell Cycle in Breast Cancer Progression and Prognosis.Pharmaceutics · 2021Review
- Article
- Sex differences in expression of immune elements emerge in children, young adults and mice with osteosarcoma.Biology of sex differences · 2021Article
- An integrative pan-cancer analysis of COPB1 based on data mining.Cancer biomarkers : section A of Disease markers · 2021Article
- Characterization of Frequently Mutated Cancer Genes and Tumor Mutation Burden in Chinese Breast Cancer.Frontiers in oncology · 2021Article
- Clinical spectrum and prognostic value of TP53 mutations in circulating tumor DNA from breast cancer patients in China.Cancer communications (London, England) · 2020Article
- GLUT1/3/4 as novel biomarkers for the prognosis of human breast cancer.Translational cancer research · 2020Article
- Gain-of-Function Mutant p53 R273H Interacts with Replicating DNA and PARP1 in Breast Cancer.Cancer research · 2020Article
- TP53 Mutations and Outcomes in Breast Cancer: Reading beyond the Headlines.Trends in cancer · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeMATERIALS AND
methodsWe performed p53 immunohistochemistry (IHC), nCounter mRNA expression assay, and DNA sequencing to determine the relationship between
resultsSeventy-seven of 174 TNBC patients were found to harbor a
conclusionAssociation between
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.